A Novel Hybrid Compound LLP2A-Ale Both Prevented and Rescued the Osteoporotic Phenotype in a Mouse Model of Glucocorticoid-Induced Osteoporosis

Geetha Mohan, Evan Yu An Lay, Haley Berka, Lorna Ringwood, Alexander Kot, Haiyan Chen, Wei Yao, Nancy E Lane

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Prolonged glucocorticoid (GC) administration causes secondary osteoporosis (GIOP) and non-traumatic osteonecrosis. LLP2A-Ale is a novel bone-seeking compound that recruits mesenchymal stem cells to the bone surface, stimulates bone formation, and increases bone mass. The purpose of this study was to determine if treatment with LLP2A-Ale alone or in combination with parathyroid hormone (PTH) could prevent or treat GIOP in a mouse model. Four-month-old male Swiss-Webster mice were randomized to a prevention study with placebo, GC (day 1–28), and GC + LLP2A-Ale (IV, day 1) or a treatment study with placebo, GC (days 1–56), GC + LLP2A-Ale (IV, day 28), GC + PTH, and GC + LLP2A-Ale + PTH (days 28–56). Mice were killed on day 28 (prevention study) or on day 56 (treatment study). The study endpoints included bone mass, bone strength, serum markers of bone turnover (P1NP and CTX-I) and angiogenesis (VEGF-A), surface-based bone turnover, and blood vessel density. LLP2A-Ale prevented GC-induced bone loss and increased mechanical strength in the vertebral body (days 28 and 56) and femur (day 56). LLP2A-Ale, PTH, and LLP2A-Ale + PTH treatment significantly increased the mineralizing surface, bone formation rate, mineral apposition rate, double-labeled surface, and serum P1NP level on day 56. LLP2A-Ale and PTH treatment increased femoral blood vessel density and LLP2A-Ale increased serum VEGF-A on day 28. Therefore, LLP2A-Ale monotherapy could be a potential option to both prevent and treat GC-induced osteoporosis and bone fragility.

Original languageEnglish (US)
Pages (from-to)1-13
Number of pages13
JournalCalcified Tissue International
DOIs
StateAccepted/In press - Sep 27 2016

Fingerprint

Glucocorticoids
Osteoporosis
Parathyroid Hormone
Phenotype
Bone and Bones
Bone Remodeling
Osteogenesis
Vascular Endothelial Growth Factor A
Blood Vessels
Placebos
Therapeutics
LLP2A compound
Osteonecrosis
Thigh
Serum
Mesenchymal Stromal Cells
Femur
Minerals
Biomarkers

Keywords

  • Angiogenesis
  • Bone loss
  • Glucocorticoid
  • LLP2A-Ale
  • Osteoporosis

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Orthopedics and Sports Medicine
  • Endocrinology

Cite this

A Novel Hybrid Compound LLP2A-Ale Both Prevented and Rescued the Osteoporotic Phenotype in a Mouse Model of Glucocorticoid-Induced Osteoporosis. / Mohan, Geetha; Lay, Evan Yu An; Berka, Haley; Ringwood, Lorna; Kot, Alexander; Chen, Haiyan; Yao, Wei; Lane, Nancy E.

In: Calcified Tissue International, 27.09.2016, p. 1-13.

Research output: Contribution to journalArticle

@article{47dc2f57e6304d369f5fc6f3c3920d46,
title = "A Novel Hybrid Compound LLP2A-Ale Both Prevented and Rescued the Osteoporotic Phenotype in a Mouse Model of Glucocorticoid-Induced Osteoporosis",
abstract = "Prolonged glucocorticoid (GC) administration causes secondary osteoporosis (GIOP) and non-traumatic osteonecrosis. LLP2A-Ale is a novel bone-seeking compound that recruits mesenchymal stem cells to the bone surface, stimulates bone formation, and increases bone mass. The purpose of this study was to determine if treatment with LLP2A-Ale alone or in combination with parathyroid hormone (PTH) could prevent or treat GIOP in a mouse model. Four-month-old male Swiss-Webster mice were randomized to a prevention study with placebo, GC (day 1–28), and GC + LLP2A-Ale (IV, day 1) or a treatment study with placebo, GC (days 1–56), GC + LLP2A-Ale (IV, day 28), GC + PTH, and GC + LLP2A-Ale + PTH (days 28–56). Mice were killed on day 28 (prevention study) or on day 56 (treatment study). The study endpoints included bone mass, bone strength, serum markers of bone turnover (P1NP and CTX-I) and angiogenesis (VEGF-A), surface-based bone turnover, and blood vessel density. LLP2A-Ale prevented GC-induced bone loss and increased mechanical strength in the vertebral body (days 28 and 56) and femur (day 56). LLP2A-Ale, PTH, and LLP2A-Ale + PTH treatment significantly increased the mineralizing surface, bone formation rate, mineral apposition rate, double-labeled surface, and serum P1NP level on day 56. LLP2A-Ale and PTH treatment increased femoral blood vessel density and LLP2A-Ale increased serum VEGF-A on day 28. Therefore, LLP2A-Ale monotherapy could be a potential option to both prevent and treat GC-induced osteoporosis and bone fragility.",
keywords = "Angiogenesis, Bone loss, Glucocorticoid, LLP2A-Ale, Osteoporosis",
author = "Geetha Mohan and Lay, {Evan Yu An} and Haley Berka and Lorna Ringwood and Alexander Kot and Haiyan Chen and Wei Yao and Lane, {Nancy E}",
year = "2016",
month = "9",
day = "27",
doi = "10.1007/s00223-016-0195-6",
language = "English (US)",
pages = "1--13",
journal = "Calcified Tissue International",
issn = "0171-967X",
publisher = "Springer New York",

}

TY - JOUR

T1 - A Novel Hybrid Compound LLP2A-Ale Both Prevented and Rescued the Osteoporotic Phenotype in a Mouse Model of Glucocorticoid-Induced Osteoporosis

AU - Mohan, Geetha

AU - Lay, Evan Yu An

AU - Berka, Haley

AU - Ringwood, Lorna

AU - Kot, Alexander

AU - Chen, Haiyan

AU - Yao, Wei

AU - Lane, Nancy E

PY - 2016/9/27

Y1 - 2016/9/27

N2 - Prolonged glucocorticoid (GC) administration causes secondary osteoporosis (GIOP) and non-traumatic osteonecrosis. LLP2A-Ale is a novel bone-seeking compound that recruits mesenchymal stem cells to the bone surface, stimulates bone formation, and increases bone mass. The purpose of this study was to determine if treatment with LLP2A-Ale alone or in combination with parathyroid hormone (PTH) could prevent or treat GIOP in a mouse model. Four-month-old male Swiss-Webster mice were randomized to a prevention study with placebo, GC (day 1–28), and GC + LLP2A-Ale (IV, day 1) or a treatment study with placebo, GC (days 1–56), GC + LLP2A-Ale (IV, day 28), GC + PTH, and GC + LLP2A-Ale + PTH (days 28–56). Mice were killed on day 28 (prevention study) or on day 56 (treatment study). The study endpoints included bone mass, bone strength, serum markers of bone turnover (P1NP and CTX-I) and angiogenesis (VEGF-A), surface-based bone turnover, and blood vessel density. LLP2A-Ale prevented GC-induced bone loss and increased mechanical strength in the vertebral body (days 28 and 56) and femur (day 56). LLP2A-Ale, PTH, and LLP2A-Ale + PTH treatment significantly increased the mineralizing surface, bone formation rate, mineral apposition rate, double-labeled surface, and serum P1NP level on day 56. LLP2A-Ale and PTH treatment increased femoral blood vessel density and LLP2A-Ale increased serum VEGF-A on day 28. Therefore, LLP2A-Ale monotherapy could be a potential option to both prevent and treat GC-induced osteoporosis and bone fragility.

AB - Prolonged glucocorticoid (GC) administration causes secondary osteoporosis (GIOP) and non-traumatic osteonecrosis. LLP2A-Ale is a novel bone-seeking compound that recruits mesenchymal stem cells to the bone surface, stimulates bone formation, and increases bone mass. The purpose of this study was to determine if treatment with LLP2A-Ale alone or in combination with parathyroid hormone (PTH) could prevent or treat GIOP in a mouse model. Four-month-old male Swiss-Webster mice were randomized to a prevention study with placebo, GC (day 1–28), and GC + LLP2A-Ale (IV, day 1) or a treatment study with placebo, GC (days 1–56), GC + LLP2A-Ale (IV, day 28), GC + PTH, and GC + LLP2A-Ale + PTH (days 28–56). Mice were killed on day 28 (prevention study) or on day 56 (treatment study). The study endpoints included bone mass, bone strength, serum markers of bone turnover (P1NP and CTX-I) and angiogenesis (VEGF-A), surface-based bone turnover, and blood vessel density. LLP2A-Ale prevented GC-induced bone loss and increased mechanical strength in the vertebral body (days 28 and 56) and femur (day 56). LLP2A-Ale, PTH, and LLP2A-Ale + PTH treatment significantly increased the mineralizing surface, bone formation rate, mineral apposition rate, double-labeled surface, and serum P1NP level on day 56. LLP2A-Ale and PTH treatment increased femoral blood vessel density and LLP2A-Ale increased serum VEGF-A on day 28. Therefore, LLP2A-Ale monotherapy could be a potential option to both prevent and treat GC-induced osteoporosis and bone fragility.

KW - Angiogenesis

KW - Bone loss

KW - Glucocorticoid

KW - LLP2A-Ale

KW - Osteoporosis

UR - http://www.scopus.com/inward/record.url?scp=84988735759&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988735759&partnerID=8YFLogxK

U2 - 10.1007/s00223-016-0195-6

DO - 10.1007/s00223-016-0195-6

M3 - Article

SP - 1

EP - 13

JO - Calcified Tissue International

JF - Calcified Tissue International

SN - 0171-967X

ER -